New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
ACC 2026 Clinical Insights: Advancing Cardiovascular CareValue of Earlier Lipid-Lowering Therapy Intensification With Evolocumab in High-Risk Populations Without Known Significant ASCVD and With Diabetes: VESALIUS-CV Insights
Dr. Robert Giugliano
- ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Nicholas Marston, MD
- Hyperlipidemia
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Erin Bohula, MD, DPhil
Nihar R. Desai, MD, MPH